REG - Genus - PRP Regulatory Progress – Canada

GenusAnnouncement

23/01/2026 17:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260123:nRSW2366Qa&default-theme=true

RNS Number : 2366Q  Genus PLC  23 January 2026

23 January 2026

Genus plc ("Genus" or the "Group")

PRP Regulatory Progress - Canada

This announcement contains inside information

Genus (LSE: GNS), a leading global animal genetics company, announces the
following update in relation to its innovative PRRS(1) Resistant Pig ("PRP")
programme.

Genus is pleased to announce that Canada has approved use of the PRP gene
edit. This approval follows years of close collaboration with multiple
Canadian regulatory agencies and represents another important step towards PRP
commercialisation in North America. Genus believes successful
commercialisation of PRP in North America requires further approvals in key
North American export markets, particularly Mexico and Japan. The Group
continues to make progress with regulators in these jurisdictions as well as
with other international regulators, including China.

PRRS is one of the most devastating global pig diseases and causes suffering
and premature death for pigs. A 2024 study from Iowa State
University(2) estimated the cost of PRRS to be $1.2 billion per annum in the
U.S. alone and a separate study indicated that PRRS increased antibiotic usage
by more than 200%(3).

For further information please contact:

Genus plc                    Tel: +44 125 634 5970

Jorgen Kokke, Chief Executive Officer

Andy Russell, Chief Financial Officer

Anand Date, Investor Relations & Sustainability Director

Burson Buchanan                   Tel: +44 207 466 5000

Charles Ryland; Mark Court; Toto Berger; Jamie Hooper

The information contained within this announcement is deemed by Genus to
constitute inside information as stipulated under the Market Abuse Regulation
(EU) no. 596/2014 (as incorporated into UK domestic law by virtue of the
European Union (Withdrawal) Act 2018 ("UK MAR"). On the publication of this
announcement via a regulatory information service, this inside information is
now considered to be in the public domain. The person responsible for
arranging the release of this announcement is Lucie Grant, Group General
Counsel and Company Secretary.

About Genus

Genus is a world-leading animal genetics company. Genus creates advances in
animal breeding and genetic improvement by applying biotechnology and sells
added value products for livestock farming and food producers. Its technology
is applicable across livestock species and is currently commercialised by
Genus in the dairy, beef and pork food production sectors.

Genus's worldwide sales are made in over seventy-five countries under the
trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen,
embryos and breeding animals with superior genetics to those animals currently
in farms. Genus's customers' animals produce offspring with greater production
efficiency, and quality, and use these to supply the global dairy and meat
supply chains.

The Group's competitive edge has been created from the ownership and control
of proprietary lines of breeding animals, the biotechnology used to improve
them and its global supply chain, technical service and sales and distribution
network. The PRP is a market leading innovation in gene editing, which Genus
is looking to commercialise in the porcine industry once regulatory approval
is gained.

With headquarters in Basingstoke, United Kingdom, Genus companies operate in
over twenty-five countries on six continents, with research laboratories
located in Madison, Wisconsin, USA.

Notes

(1) Porcine Reproductive and Respiratory Syndrome

(2)
https://research.iastate.edu/2024/07/30/growing-losses-from-prrs-cost-pork-producers-1-2-billion-per-year-new-study-shows/
(https://research.iastate.edu/2024/07/30/growing-losses-from-prrs-cost-pork-producers-1-2-billion-per-year-new-study-shows/)

(3)
https://dr.lib.iastate.edu/entities/publication/4e3cd302-5ae9-4185-8ead-405e0d4ec2f2
(https://dr.lib.iastate.edu/entities/publication/4e3cd302-5ae9-4185-8ead-405e0d4ec2f2)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCZZGZMNFZGVZM



            Copyright 2019 Regulatory News Service, all rights reserved